GlassScriptPhysician profile
Amir Izhar
NPI 1154361947
$847.26
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $214 · 2023: $86.09 · 2024: $62.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129 · Education: $19.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $128.96 |
| Education | $19.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $228.89 | 2019-2020 | |
| Gilead Sciences, INC. | $124.94 | 2019 | |
| Bard Peripheral Vascular, INC. | $83.95 | 2019 | |
| Mallinckrodt Hospital Products INC. | $83.01 | 2023 | Terlivaz |
| Genzyme Corporation | $79.63 | 2020 | |
| Akcea Therapeutics, INC. | $71.88 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.15 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.80 | 2024 | Gattex |
| Otsuka America Pharmaceutical, INC. | $20.14 | 2019 | |
| Travere Therapeutics, INC. | $19.97 | 2023-2024 | |
| Vifor Pharma, INC. | $19.77 | 2019 | |
| Fresenius USA Marketing, INC. | $19.40 | 2020 | |
| Mallinckrodt Enterprises LLC | $16.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Izhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.